PCSK9 and metabolic dysfunction-associated steatotic liver disease: Besides targeting PCSK9 mRNA, miR-483 likely targets several genes and pathways involved in nonalcoholic fatty liver disease (NAFLD), including IL1B, IL6, TGFB1, and monocyte chemoattractant protein 1 (20).